An interesting observation was that whereas the JAK2-targeting drugs blocked STAT5 activation and MPN cell growth at relatively low concentrations, much higher concentrations of the STAT5 blockers were required to counteract proliferation in MPN cells (Figure 5). Here, STAT5B is linked to myeloproliferative neoplasm.